Victory Capital Management’s Regulus Therapeutics RGLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-386,666
Closed -$677K 2542
2025
Q1
$677K Sell
386,666
-3,220
-0.8% -$4.25K ﹤0.01% 1949
2024
Q4
$616K Sell
389,886
-8,980
-2% -$13.8K ﹤0.01% 1974
2024
Q3
$626K Buy
398,866
+37,480
+10% +$62K ﹤0.01% 1950
2024
Q2
$645K Sell
361,386
-6,760
-2% -$15.7K ﹤0.01% 1897
2024
Q1
$1.06M Buy
368,146
+96,410
+35% +$157K ﹤0.01% 1713
2023
Q4
$348K Buy
271,736
+38,529
+17% +$51.3K ﹤0.01% 2087
2023
Q3
$322K Buy
233,207
+11,701
+5% +$17K ﹤0.01% 2103
2023
Q2
$326K Hold
221,506
﹤0.01% 2096
2023
Q1
$188K Hold
221,506
﹤0.01% 2256
2022
Q4
$303K Hold
221,506
﹤0.01% 2170
2022
Q3
$377K Hold
221,506
﹤0.01% 2169
2022
Q2
$459K Sell
221,506
-1,797
-0.8% -$4.36K ﹤0.01% 2091
2022
Q1
$664K Sell
223,303
-51
-0% -$133 ﹤0.01% 2009
2021
Q4
$704K Buy
223,354
+633
+0.3% +$2.81K ﹤0.01% 1987
2021
Q3
$1.54M Sell
222,721
-1,073
-0.5% -$7.86K ﹤0.01% 1680
2021
Q2
$1.82M Buy
223,794
+1,074
+0.5% +$12K ﹤0.01% 1657
2021
Q1
$3.47M Buy
222,720
+172,721
+345% +$2.56M ﹤0.01% 1470
2020
Q4
$675K Buy
+49,999
New +$367K ﹤0.01% 1929
2020
Q2
Sell
-583
Closed -$2K 3121
2020
Q1
$2K Buy
+583
New +$5.08K ﹤0.01% 3667
2019
Q4
Sell
-299
Closed -$2K 3144
2019
Q3
$2K Buy
+299
New +$2.44K ﹤0.01% 3640
2018
Q1
Sell
-2,731
Closed -$341K 1898
2017
Q4
$341K Buy
2,731
+421
+18% +$53.3K ﹤0.01% 1355
2017
Q3
$347K Buy
+2,310
New +$291K ﹤0.01% 1357

Other funds holding RGLS

Victory Capital Management's RGLS Position: Q2 2025 in Review

Victory Capital Management sold out of Regulus Therapeutics (RGLS) in Q2 2025, closing a stake of 386,666 shares — an estimated $677K sold.

Victory Capital Management first reported a position in RGLS in Q3 2017 and held it in 22 quarters. The position peaked at $3.47M in Q1 2021. 0 funds tracked by Wall St. Rank hold RGLS as of Q2 2025.

  • Victory Capital Management reported no remaining Regulus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Victory Capital Management sold 386,666 Regulus Therapeutics shares in Q2 2025, an estimated $677K.
  • Victory Capital Management first reported a position in Regulus Therapeutics in Q3 2017 and held it in 22 quarters.
  • Victory Capital Management's Regulus Therapeutics position peaked at $3.47M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2025.

Based on Victory Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.